CN107375938A - 一种盐酸氨基葡萄糖的粘合剂、片剂及其制备方法 - Google Patents
一种盐酸氨基葡萄糖的粘合剂、片剂及其制备方法 Download PDFInfo
- Publication number
- CN107375938A CN107375938A CN201710734470.4A CN201710734470A CN107375938A CN 107375938 A CN107375938 A CN 107375938A CN 201710734470 A CN201710734470 A CN 201710734470A CN 107375938 A CN107375938 A CN 107375938A
- Authority
- CN
- China
- Prior art keywords
- microcrystalline cellulose
- pvp
- tablet
- compound
- adhesive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001070 adhesive effect Effects 0.000 title claims abstract description 30
- 239000000853 adhesive Substances 0.000 title claims abstract description 29
- CHVZQMAANSUXJU-JJKGCWMISA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanamide;hydrochloride Chemical compound Cl.NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO CHVZQMAANSUXJU-JJKGCWMISA-N 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 19
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 19
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 19
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 19
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 claims abstract description 16
- 229960001911 glucosamine hydrochloride Drugs 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 12
- 238000005550 wet granulation Methods 0.000 claims abstract description 9
- 239000000080 wetting agent Substances 0.000 claims abstract description 8
- -1 PVP compound Chemical class 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000005469 granulation Methods 0.000 claims description 13
- 230000003179 granulation Effects 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 8
- 235000019441 ethanol Nutrition 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 5
- 238000009501 film coating Methods 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 235000020985 whole grains Nutrition 0.000 claims description 5
- 239000007888 film coating Substances 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 15
- 239000012535 impurity Substances 0.000 abstract description 9
- 230000008569 process Effects 0.000 abstract description 6
- 238000007908 dry granulation Methods 0.000 abstract description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 29
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 16
- 238000001035 drying Methods 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 11
- 229920002472 Starch Polymers 0.000 description 10
- 235000019698 starch Nutrition 0.000 description 10
- 239000000463 material Substances 0.000 description 9
- 229920003081 Povidone K 30 Polymers 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 5
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 230000001133 acceleration Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- XUKUURHRXDUEBC-SXOMAYOGSA-N (3s,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SXOMAYOGSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000002932 luster Substances 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- UBDZFAGVPPMTIT-UHFFFAOYSA-N 2-aminoguanidine;hydron;chloride Chemical compound [Cl-].NC(N)=N[NH3+] UBDZFAGVPPMTIT-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 230000008414 cartilage metabolism Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000000323 shoulder joint Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000003857 wrist joint Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710734470.4A CN107375938B (zh) | 2017-08-24 | 2017-08-24 | 一种盐酸氨基葡萄糖的粘合剂、片剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710734470.4A CN107375938B (zh) | 2017-08-24 | 2017-08-24 | 一种盐酸氨基葡萄糖的粘合剂、片剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107375938A true CN107375938A (zh) | 2017-11-24 |
CN107375938B CN107375938B (zh) | 2020-07-07 |
Family
ID=60346624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710734470.4A Active CN107375938B (zh) | 2017-08-24 | 2017-08-24 | 一种盐酸氨基葡萄糖的粘合剂、片剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107375938B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1364464A (zh) * | 2002-01-29 | 2002-08-21 | 郑刚 | 盐酸氨基葡萄糖药物组合物 |
WO2008146104A2 (en) * | 2007-06-01 | 2008-12-04 | Hertek Sa | Stable liquid composition of chondroitinsulfate and glucosamine |
CN103800290A (zh) * | 2012-11-07 | 2014-05-21 | 杭州赛利药物研究所有限公司 | 盐酸氨基葡萄糖微丸制剂及其制备方法 |
-
2017
- 2017-08-24 CN CN201710734470.4A patent/CN107375938B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1364464A (zh) * | 2002-01-29 | 2002-08-21 | 郑刚 | 盐酸氨基葡萄糖药物组合物 |
WO2008146104A2 (en) * | 2007-06-01 | 2008-12-04 | Hertek Sa | Stable liquid composition of chondroitinsulfate and glucosamine |
CN103800290A (zh) * | 2012-11-07 | 2014-05-21 | 杭州赛利药物研究所有限公司 | 盐酸氨基葡萄糖微丸制剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN107375938B (zh) | 2020-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shihora et al. | Superdisintegrants, utility in dosage forms: a quick review | |
CN102579381B (zh) | 盐酸胍法辛缓释制剂及其制备方法 | |
CN102292073B (zh) | 苯达莫司汀的固体剂型 | |
WO2006123678A1 (ja) | ドロキシドパを含有する安定な錠剤 | |
JPS6191118A (ja) | チアミン塩の顆粒,その製造法および錠剤 | |
AU2010274589A1 (en) | Oral pharmaceutical composition of rasagiline and process for preparing thereof | |
CN103301084A (zh) | 一种盐酸小檗碱片及其制备方法 | |
CN102138911B (zh) | 一种双丙戊酸钠缓释片及其制备方法 | |
CN109875972B (zh) | 一种奥美沙坦酯氨氯地平药物组合物 | |
CN105434386B (zh) | 一种含有高水溶性活性成分的缓释片剂及其制备方法 | |
CN112603900A (zh) | 含[(4-羟基-1-甲基-7-苯氧基-异喹啉-3-羰基)-氨基]-乙酸的固体制剂 | |
CN103263395A (zh) | 一种替米沙坦片剂及其制备方法 | |
CN102764254B (zh) | 一种左乙拉西坦药物组合物及其制备方法 | |
CN105343028A (zh) | 一种诺氟沙星的药物组合物及其制备方法 | |
TWI721946B (zh) | 色瑞替尼調配物 | |
CN104940152A (zh) | 一种含有琥珀酸索利那新的药物组合物 | |
JP2006176496A (ja) | 固形剤およびその製造方法 | |
CN109125270B (zh) | 一种固体制剂及其制备方法 | |
CN102755300A (zh) | 一种伏立康唑组合物及其制备方法 | |
Donea et al. | Determination of the impact of the compression force by evaluating the mechanical and release properties of mesalazine tablets | |
CN107375938A (zh) | 一种盐酸氨基葡萄糖的粘合剂、片剂及其制备方法 | |
WO2021196982A1 (zh) | 一种抗心律失常的药物组合物及制备方法 | |
CN104666263B (zh) | 一种含有左乙拉西坦的片剂及其制备方法 | |
CN103505466A (zh) | 含有盐酸二甲双胍与格列美脲的固体复方制剂及其制备方法和用途 | |
CN111000812B (zh) | 一种拉考沙胺片的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210402 Address after: 210046 room 2011, building A3, No.9, Weidi Road, Xianlin University Town, Xianlin street, Qixia District, Nanjing City, Jiangsu Province Patentee after: Nanjing Nanyao investment management consulting partnership (L.P.) Address before: 210046 room 113, building F6, No.9, Xianlin Weidi Road, Qixia District, Nanjing City, Jiangsu Province Patentee before: NANJING ZEHENG PHARMACEUTICAL SCIENCE & TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240108 Address after: Room 903, 905, and 907, Building D6, Jiangsu Life Science Park, No. 9 Weidi Road, Xianlin Street, Qixia District, Nanjing City, Jiangsu Province, 210000 Patentee after: NANJING ZEHENG PHARMACEUTICAL SCIENCE & TECHNOLOGY Co.,Ltd. Address before: 210046 room 2011, building A3, No.9, Weidi Road, Xianlin University Town, Xianlin street, Qixia District, Nanjing City, Jiangsu Province Patentee before: Nanjing Nanyao investment management consulting partnership (L.P.) |